Literature DB >> 20332231

Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.

Vinata B Lokeshwar1, Luis E Lopez, Daniel Munoz, Andrew Chi, Samir P Shirodkar, Soum D Lokeshwar, Diogo O Escudero, Neetika Dhir, Norman Altman.   

Abstract

4-Methylumbelliferone (4-MU) is a hyaluronic acid (HA) synthesis inhibitor with anticancer properties; the mechanism of its anticancer effects is unknown. We evaluated the effects of 4-MU on prostate cancer cells. 4-MU inhibited proliferation, motility, and invasion of DU145, PC3-ML, LNCaP, C4-2B, and/or LAPC-4 cells. At IC(50) for HA synthesis (0.4 mmol/L), 4-MU induced >3-fold apoptosis in prostate cancer cells, which could be prevented by the addition of HA. 4-MU induced caspase-8, caspase-9, and caspase-3 activation, PARP cleavage, upregulation of Fas-L, Fas, FADD and DR4, and downregulation of bcl-2, phosphorylated bad, bcl-XL, phosphorylated Akt, phosphorylated IKB, phosphorylated ErbB2, and phosphorylated epidermal growth factor receptor. At IC(50), 4-MU also caused >90% inhibition of NF-kappaB reporter activity, which was prevented partially by the addition of HA. With the exception of caveolin-1, HA reversed the 4-MU-induced downregulation of HA receptors (CD44 and RHAMM), matrix-degrading enzymes (MMP-2 and MMP-9), interleukin-8, and chemokine receptors (CXCR1, CXCR4, and CXCR7) at the protein and mRNA levels. Expression of myristoylated-Akt rescued 4-MU-induced apoptosis and inhibition of cell growth and interleukin-8, RHAMM, HAS2, CD44, and MMP-9 expression. Oral administration of 4-MU significantly decreased PC3-ML tumor growth (>3-fold) when treatment was started either on the day of tumor cell injection or after the tumors became palpable, without organ toxicity, changes in serum chemistry, or body weight. Tumors from 4-MU-treated animals showed reduced microvessel density ( approximately 3-fold) and HA expression but increased terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells and expression of apoptosis-related molecules. Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332231      PMCID: PMC2848908          DOI: 10.1158/0008-5472.CAN-09-3185

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54.

Authors:  Gina Lisignoli; Sandra Cristino; Anna Piacentini; Carola Cavallo; Arnold I Caplan; Andrea Facchini
Journal:  J Cell Physiol       Date:  2006-05       Impact factor: 6.384

2.  Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells.

Authors:  Shibnath Ghatak; Suniti Misra; Bryan P Toole
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

3.  Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.

Authors:  Stephen J Freedland; David B Seligson; Alvin Y Liu; Allan J Pantuck; Sun H Paik; Steve Horvath; Jeffrey A Wieder; Amnon Zisman; David Nguyen; Cho-Lea Tso; Aarno V Palotie; Arie S Belldegrun
Journal:  Prostate       Date:  2003-04-01       Impact factor: 4.104

4.  4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3.

Authors:  Anne Kultti; Sanna Pasonen-Seppänen; Marjo Jauhiainen; Kirsi J Rilla; Riikka Kärnä; Emma Pyöriä; Raija H Tammi; Markku I Tammi
Journal:  Exp Cell Res       Date:  2009-03-13       Impact factor: 3.905

5.  Effect of a hyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell adhesion and locomotion.

Authors:  Daisuke Kudo; Atsushi Kon; Shuichi Yoshihara; Ikuko Kakizaki; Mutsuo Sasaki; Masahiko Endo; Keiichi Takagaki
Journal:  Biochem Biophys Res Commun       Date:  2004-09-03       Impact factor: 3.575

6.  Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4.

Authors:  Verena Voelcker; Carl Gebhardt; Marco Averbeck; Anja Saalbach; Verena Wolf; Falk Weih; Jonathan Sleeman; Ulf Anderegg; Jan Simon
Journal:  Exp Dermatol       Date:  2007-11-21       Impact factor: 3.960

7.  The hyaluronan synthesis inhibitor 4-methylumbelliferone prevents keratinocyte activation and epidermal hyperproliferation induced by epidermal growth factor.

Authors:  Kirsi Rilla; Sanna Pasonen-Seppänen; Jarno Rieppo; Markku Tammi; Raija Tammi
Journal:  J Invest Dermatol       Date:  2004-10       Impact factor: 8.551

8.  Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.

Authors:  J Timothy Posey; Mark S Soloway; Sinan Ekici; Mario Sofer; Francisco Civantos; Robert C Duncan; Vinata B Lokeshwar
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism.

Authors:  David Murray; Mary Morrin; Susan McDonnell
Journal:  Anticancer Res       Date:  2004 Mar-Apr       Impact factor: 2.480

10.  Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.

Authors:  Bhavik Desai; Michael J Rogers; Meenakshi A Chellaiah
Journal:  Mol Cancer       Date:  2007-03-07       Impact factor: 27.401

View more
  77 in total

1.  Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan.

Authors:  Aditya G Kohli; Saul Kivimäe; Matthew R Tiffany; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-20       Impact factor: 9.776

2.  Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis.

Authors:  Andrew Chi; Samir P Shirodkar; Diogo O Escudero; Obi O Ekwenna; Travis J Yates; Rajinikanth Ayyathurai; Michael Garcia-Roig; Jeffrey C Gahan; Murugesan Manoharan; Vincent G Bird; Vinata B Lokeshwar
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

3.  Hyaluronan synthase 2 protects skin fibroblasts against apoptosis induced by environmental stress.

Authors:  Yan Wang; Mark E Lauer; Sanjay Anand; Judith A Mack; Edward V Maytin
Journal:  J Biol Chem       Date:  2014-09-29       Impact factor: 5.157

4.  Effects of 4-methylumbelliferone and high molecular weight hyaluronic acid on the inflammation of corneal stromal cells induced by LPS.

Authors:  Fang Li; Peng Hao; Guangjie Liu; Weiyi Wang; Ruifang Han; Zhixin Jiang; Xuan Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-06       Impact factor: 3.117

5.  C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer.

Authors:  Travis J Yates; Judith Knapp; Miguel Gosalbez; Soum D Lokeshwar; Christopher S Gomez; Anaid Benitez; Obi O Ekwenna; Ezekiel E Young; Murugesan Manoharan; Vinata B Lokeshwar
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

6.  Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis.

Authors:  Yue Leng; Ammara Abdullah; Michael K Wendt; Sarah Calve
Journal:  Matrix Biol       Date:  2018-08-18       Impact factor: 11.583

7.  Inhibition of Hyaluronic Acid Synthesis Decreases Endometrial Cell Attachment, Migration, and Invasion.

Authors:  Jessica E McLaughlin; Marlen Tellez Santos; Peter A Binkley; Mubeen Sultana; Rajeshwar R Tekmal; Robert S Schenken; Jennifer F Knudtson
Journal:  Reprod Sci       Date:  2020-02-03       Impact factor: 3.060

Review 8.  The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer.

Authors:  Hannah E Majeski; Jing Yang
Journal:  Mol Pharmacol       Date:  2016-10-14       Impact factor: 4.436

9.  Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look.

Authors:  Clifford J Whatcott; Haiyong Han; Richard G Posner; Galen Hostetter; Daniel D Von Hoff
Journal:  Cancer Discov       Date:  2011-09       Impact factor: 39.397

10.  Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.

Authors:  Anaid Benitez; Travis J Yates; N Shamaldevi; Tim Bowen; Vinata B Lokeshwar
Journal:  J Urol       Date:  2012-12-07       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.